强生公司已正式向欧洲药品管理局提交申请,寻求批准其药物Tecvayli®与Darzalex®皮下制剂联合疗法,用于治疗复发或难治性多发性骨髓瘤患者。
强生公司已正式向欧洲药品管理局提交申请,寻求批准其药物Tecvayli®与Darzalex®皮下制剂联合疗法,用于治疗复发或难治性多发性骨髓瘤患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.